Core Viewpoint - China Zhongfu (01763) issued a profit warning, leading to a decline of over 7% in its stock price, currently down 6.54% at HKD 20.3, with a trading volume of HKD 11.47 million [1] Financial Performance - The company expects annual revenue to be approximately RMB 6.979 billion to RMB 7.206 billion, representing a year-on-year decrease of about 5% to 8% [1] - Net profit is projected to be around RMB 611 million to RMB 655 million, indicating a year-on-year decline of approximately 25% to 30% [1] - Profit attributable to equity shareholders is estimated to be between RMB 302 million to RMB 322 million, reflecting a year-on-year decrease of about 20% to 25% [1] Operational Status - The company stated that its operations are currently normal, and the revenue decrease for the fiscal year 2025 is primarily due to a decline in the revenue from its nuclear medical equipment division [1] - The profit reduction is mainly attributed to tax payments and late fees incurred by its subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd. [1]
港股异动 | 中国同辐(01763)盈警后跌超7% 预计去年纯利跌最多25% 收入下滑最多8%